Moderna meets preliminary 2023 COVID vaccine sales target

Moderna reported preliminary 2023 sales of $6.7 billion of its COVID vaccine, exceeding the lower end of its full-year forecast, while reiterating its goal of returning to sales growth in 2025. The company’s shares were up 1.5% in pre-market trading.

Share This Post:

POPULAR POSTS
FOLLOW US
Like Us On Facebook
Follow Us On Twitter
Subscribe To Our Channel
TikTok
LIVE STREAM